- Home
- MPB vs KROS Comparison
MPB vs KROS Comparison
Compare MPB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPB | KROS |
|---|---|---|
| Founded | 1868 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.9M | 655.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MPB | KROS |
|---|---|---|
| Price | $31.06 | $20.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $37.00 | $22.20 |
| AVG Volume (30 Days) | 86.8K | ★ 742.6K |
| Earning Date | 01-21-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.40 | 1.57 |
| Revenue | $208,869,000.00 | ★ $246,718,000.00 |
| Revenue This Year | $26.19 | $6,924.79 |
| Revenue Next Year | $28.25 | N/A |
| P/E Ratio | $12.96 | ★ $12.87 |
| Revenue Growth | 20.73 | ★ 37798.31 |
| 52 Week Low | $22.50 | $9.12 |
| 52 Week High | $33.24 | $22.55 |
Technical Indicators
Market Signals| Indicator | MPB | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 54.81 |
| Support Level | $31.64 | $19.76 |
| Resistance Level | $33.24 | $21.76 |
| Average True Range (ATR) | 0.58 | 0.68 |
| MACD | -0.19 | -0.24 |
| Stochastic Oscillator | 2.21 | 28.09 |
Price Performance
Historical ComparisonAbout MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.